StockMarketWire.com - Liquid biopsy company Angle said Monday it continued to expect the clinical and analytical studies of its metastatic breast cancer clinical study to complete in second half of 2018 as patient enrolment was making 'encouraging' progress.

The company said two additional centres were opened to enrolment at the end of May, taking the total number of US cancer centres actively recruiting patients for the ANG-002 clinical study and enrolment to four.

'We are pleased to announce today that patient enrolment to date for our FDA study has been encouraging and we now have four leading US cancer centres actively recruiting subjects for the study,' said Angle Founder and Chief Executive, Andrew Newland.

Over 80 subjects had so far been enrolled out of a required 400 subjects for the study (200 metastatic breast cancer patients and 200 healthy volunteers of a similar age and demographic.

The primary objective of the study was the cytological evaluation of harvested cells by a qualified pathologist to confirm that CTCs were harvested from metastatic breast cancer patients but not from healthy volunteers.

'The progress reported today suggests that both the clinical study and the associated analytical studies will complete, as planned, in H2 CY 2018,' the company said.

At 8:04am: [LON:AGL] Angle PLC share price was +1p at 56p



Story provided by StockMarketWire.com